|Bid||7.96 x 800|
|Ask||7.97 x 800|
|Day's Range||7.80 - 8.04|
|52 Week Range||2.23 - 12.22|
|Beta (3Y Monthly)||2.44|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ArQule (ARQL) delivered earnings and revenue surprises of 11.11% and -80.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
On Wednesday, August 7, Arqule (NASDAQ: ARQL ) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. Earnings and Revenue Wall Street expects an EPS loss of 9 cents ...
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
ArQule (ARQL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
Biotech sector exchange traded funds rallied Monday after Pfizer (NYSE: PFE) said it would acquire Array Biopharma Inc. (NasdaqGS: ARRY) in a $10.6 billion deal to bolster its portfolio of cancer fighting ...
Close on the heels of a 30% rally Friday on the back of positive results from an early stage study of its leukemia drug candidate, ArQule announced preliminary results from a Phase 1/2 study of its pan-AKT inhibitor miransertib, or ARQ 092, in patients with PIK3CA-related Overgrowth Spectrum, or PROS, and Proteus syndrome, or PS. The data was presented at the European Society of Human Genetics Conference in Gothenburg, Sweden. The recommended initial dose for the registrational study was defined as a 15mg/square meter once-daily dose, with a subsequent maximum dose increase to 25 mg/square meter.
For biotech stocks, the week was back loaded with multiple conferences scheduled for the later half of the week. Nevertheless, there were volatile moves in some low-float, thinly traded stocks. Looking ...
ArQule (NASDAQ:ARQL) began the day and ended the week with a bang as the company's latest blood cancer treatment has shown early signs of promise in helping patients with tumors heal.The Woburn, Mass.-based pharmaceutical business announced its preliminary data from a Phase 1 trial in regards to its investigational cancer drug ARQ 531. The company's early-stage trial is still ongoing, and it examined the effects of several different doses of the drug in 34 patients suffering from advanced chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), Richter's Transformation, Waldenstrom macroglobulinemia as well as other B-cell Non-Hodgkin lymphomas.ArQule's Phase 1 trials are designed to establish a recommended dose of a new drug for study for the Phase 2 trials. Researchers from the study looking at ARQ 531 said patients were fine at dosages of up to 65 milligrams once a day.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe drug displayed promising anti-tumor activity in some patients, according to the company. "We are now focused on finalizing the recommended Phase 2 dose and planning for the expansion of our clinical efforts with ARQ 531 into later stage trials across multiple indications as a single agent and as a combination therapy," said ArQule Chief Medical Officer Brian Schwartz in a statement.ARQL stock is soaring a whopping 32.6% following the company's news on Friday. This helped push the company's per share price to a 12-year high of $8.34. More From InvestorPlace * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Stocks to Buy for the Coming Recession * 7 High-Quality Cheap Stocks to Buy With $10 Compare Brokers The post ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results appeared first on InvestorPlace.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ArQule, Inc. (NASDAQ: ARQL ) shares were up ...